IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 11.25
(0.0%)
SEK 11.25
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -122.73 Million SEK | -61.94% |
| 2022 | -111.23 Million SEK | -165.94% |
| 2021 | 168.69 Million SEK | 10040.54% |
| 2020 | -1.69 Million SEK | 98.24% |
| 2019 | -96.2 Million SEK | -29.87% |
| 2018 | -74.07 Million SEK | -639.35% |
| 2017 | -10.01 Million SEK | 79.56% |
| 2016 | -49.02 Million SEK | -76.4% |
| 2015 | -27.78 Million SEK | -99.94% |
| 2014 | -13.89 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -9.52 Million SEK | -726.48% |
| 2024 Q3 | -36.71 Million SEK | -285.58% |
| 2024 Q1 | -1.15 Million SEK | 96.76% |
| 2023 Q2 | -44.15 Million SEK | -3984.27% |
| 2023 Q4 | -35.57 Million SEK | -3194.35% |
| 2023 FY | -180.13 Million SEK | -61.94% |
| 2023 Q3 | -1.08 Million SEK | 97.55% |
| 2023 Q1 | -1.08 Million SEK | 96.7% |
| 2022 Q3 | -23.7 Million SEK | 11.39% |
| 2022 Q2 | -26.75 Million SEK | 7.07% |
| 2022 Q1 | -28.78 Million SEK | -26.02% |
| 2022 FY | -111.23 Million SEK | -165.94% |
| 2022 Q4 | -32.78 Million SEK | -38.3% |
| 2021 Q2 | -915 Thousand SEK | -43.87% |
| 2021 FY | 168.69 Million SEK | 10040.54% |
| 2021 Q4 | -22.84 Million SEK | -114.21% |
| 2021 Q1 | -636 Thousand SEK | 95.08% |
| 2021 Q3 | 160.75 Million SEK | 17668.42% |
| 2020 Q2 | -17.68 Million SEK | -40.7% |
| 2020 Q3 | -22.08 Million SEK | -24.9% |
| 2020 Q4 | -12.92 Million SEK | 41.5% |
| 2020 FY | -1.69 Million SEK | 98.24% |
| 2020 Q1 | -12.56 Million SEK | 35.71% |
| 2019 FY | -96.2 Million SEK | -29.87% |
| 2019 Q4 | -19.54 Million SEK | -16.89% |
| 2019 Q3 | -16.72 Million SEK | 26.81% |
| 2019 Q2 | -22.84 Million SEK | 0.0% |
| 2019 Q1 | - SEK | 100.0% |
| 2018 Q1 | - SEK | 100.0% |
| 2018 FY | -74.07 Million SEK | -639.35% |
| 2018 Q4 | -13.36 Million SEK | -11.44% |
| 2018 Q2 | -17.14 Million SEK | 0.0% |
| 2018 Q3 | -11.99 Million SEK | 30.04% |
| 2017 Q1 | -8.01 Million SEK | 20.6% |
| 2017 Q2 | -7.35 Million SEK | 8.29% |
| 2017 Q3 | -17.99 Million SEK | -144.71% |
| 2017 Q4 | -6.76 Million SEK | 62.42% |
| 2017 FY | -10.01 Million SEK | 79.56% |
| 2016 Q1 | -11.75 Million SEK | 0.0% |
| 2016 FY | -49.02 Million SEK | -76.4% |
| 2016 Q3 | -6.23 Million SEK | 10.98% |
| 2016 Q2 | -7 Million SEK | 40.38% |
| 2016 Q4 | -10.09 Million SEK | -61.89% |
| 2015 FY | -27.78 Million SEK | -99.94% |
| 2014 FY | -13.89 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 23.618% |
| Ziccum AB (publ) | -23.28 Million SEK | -427.072% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 135.44% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 393.713% |
| Mendus AB (publ) | 28.48 Million SEK | 530.842% |
| Genovis AB (publ.) | 54 Million SEK | 327.281% |
| Intervacc AB (publ) | -13.79 Million SEK | -789.764% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 5753.339% |
| Active Biotech AB (publ) | -1.67 Million SEK | -7227.403% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 1331.898% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 557.604% |
| Aptahem AB (publ) | 2.63 Million SEK | 4765.542% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -3487.664% |
| Kancera AB (publ) | -1.96 Million SEK | -6146.005% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 159494.805% |
| Fluicell AB (publ) | 1.73 Million SEK | 7161.795% |
| Saniona AB (publ) | 11.78 Million SEK | 1141.796% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -2298.554% |
| Biovica International AB (publ) | 6.87 Million SEK | 1884.703% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | -427.14% |
| AcouSort AB (publ) | 8.38 Million SEK | 1563.035% |
| Xintela AB (publ) | 78 Thousand SEK | 157451.282% |
| Abliva AB (publ) | -35.66 Million SEK | -244.149% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 16.451% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 4472.426% |
| OncoZenge AB (publ) | 3000.00 SEK | 4091233.333% |
| Amniotics AB (publ) | -1.93 Million SEK | -6259.275% |
| 2cureX AB (publ) | -37.48 Million SEK | -227.404% |
| CombiGene AB (publ) | -21.29 Million SEK | -476.468% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -28915.13% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 110.863% |
| Camurus AB (publ) | 1.58 Billion SEK | 107.765% |
| Corline Biomedical AB | 28.38 Million SEK | 532.467% |
| Isofol Medical AB (publ) | -34.41 Million SEK | -256.629% |
| I-Tech AB | 27.56 Million SEK | 545.237% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 272.984% |
| Cyxone AB (publ) | 2.61 Million SEK | 4800.651% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 3706.641% |
| Biosergen AB | -456 Thousand SEK | -26815.351% |
| Cantargia AB (publ) | -3.45 Million SEK | -3456.476% |
| NextCell Pharma AB | -43.74 Million SEK | -180.547% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | -1234.936% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 1194.053% |
| Nanologica AB (publ) | -76 Thousand SEK | -161392.105% |
| SynAct Pharma AB | -778 Thousand SEK | -15675.578% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -63492.746% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | -849.807% |
| Lipum AB (publ) | 53 Thousand SEK | 231673.585% |
| BioInvent International AB (publ) | 71.46 Million SEK | 271.75% |
| Alzinova AB (publ) | 19.87 Million SEK | 717.561% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 438.12% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 8489.086% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -818126.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 7502.533% |
| Simris Alg AB (publ) | 2 Million SEK | 6215.296% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -3328.324% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 446.824% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -11600.095% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 4017.459% |